Список литературы

1. Детская гематология Под ред: А.Г. Румянцева, А.А. Масчана, Е.В. Жуковской. 2015. 656 p.

2. Pui C.-H. Childhood leukemias. 2012. 880 p.

3. Савченко В.Г., Паровичникова Е.Н. Острые лейкозы//Клиническая онкогематология: руководство для врачей. Под ред. Волковой М.А. 2-е изд., перераб. и доп. 2007. P. 409 - 502.

4. Паровичникова Е.Н. et al. Клинический протокол ОМЛ-01.10 по лечению острых миелоидных лейкозов взрослых//Программное лечение заболеваний крови, под ред. Савченко В.Г. М.: Практика, 2012. P. 153 - 207.

5. Shallis R.M. et al. Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges.//Blood Rev. 2019. Vol. 36. P. 70 - 87.

6. Swerdlow S.H. et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms//Blood. 2016.

7. Arber D.A. et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia//Blood. 2016.

8. Acute Myeloid Leukemia. National Comprehensive Cancer Network (NCCN) Guidelines. 2-2020. [Electronic resource]. URL: https://www.nccn.org/professionals/physician_gls/pdf/aml.pdf.

9. Kulsoom B. et al. Clinical presentation of acute myeloid leukaemia - A decade-long institutional follow-up.//J. Pak. Med. Assoc. 2017. Vol. 67, N 12. P. 1837 - 1842.

10. Godley L.A. Inherited predisposition to acute myeloid leukemia.//Semin. Hematol. 2014. Vol. 51, N 4. P. 306 - 321.

11. Rubnitz J.E., Gibson B., Smith F.O. Acute Myeloid Leukemia//Hematology/Oncology Clinics of North America. 2010. Vol. 24, N 1. P. 35 - 63.

12. Agis H. et al. A comparative study on demographic, hematological, and cytogenetic findings and prognosis in acute myeloid leukemia with and without leukemia cutis.//Ann. Hematol. 2002. Vol. 81, N 2. P. 90 - 95.

13. Avni B. et al. Clinical implications of acute myeloid leukemia presenting as myeloid sarcoma.//Hematol. Oncol. 2012. Vol. 30, N 1. P. 34 - 40.

14. Creutzig U. et al. Diagnosis and management of acute myeloid leukemia in children and adolescents: Recommendations from an international expert panel//Blood. American Society of Hematology, 2012. Vol. 120, N 16. P. 3167 - 3205.

15. Ku G.H. et al. Venous thromboembolism in patients with acute leukemia: Incidence, risk factors, and effect on survival//Blood. 2009. Vol. 113, N 17. P. 3911 - 3917.

16. Муфтахова Г.М., Аксенова М.Е. Поздние эффекты противоопухолевой терапии со стороны мочеполовой системы (отсроченное влияние противоопухолевой терапии на органы мочеполовой системы)//Российский журнал детской гематологии и онкологии. 2019. Vol. 5, N 4. P. 114 - 119.

17. Fang R.C., Aboulafia D.M. HIV infection and myelodysplastic syndrome/acute myeloid leukemia//HIV-Associated Hematological Malignancies. 2016. P. 133 - 144.

18. Freeman A.J. et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection.//Hepatology. 2001. Vol. 34, N 4 Pt 1. P. 809 - 816.

19. Ribas A. et al. How important is hepatitis C virus (HCV)-infection in persons with acute leukemia?//Leuk. Res. 1997. Vol. 21, N 8. P. 785 - 788.

20. Lam M.T. et al. Herpes simplex infection in acute myelogenous leukemia and other hematologic malignancies: a prospective study.//Cancer. 1981. Vol. 48, N 10. P. 2168 - 2171.

21. Averbuch D. et al. Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: Guidelines of the 4th European conference on Infections in Leukemia (ECIL-4, 2011)//Haematologica. 2013. Vol. 98, N 12. P. 1836 - 1847.

22. Averbuch D. et al. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: Summary of the 2011 4th European Conference on Infections in Leukemia//Haematologica. 2013. Vol. 98, N 12. P. 1826 - 1835.

23. Leahy M.F., Mukhtar S.A. From blood transfusion to patient blood management: a new paradigm for patient care and cost assessment of blood transfusion practice.//Intern. Med. J. 2012. Vol. 42, N 3. P. 332 - 338.

24. H. et al. Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European LeukemiaNet//Blood. 2010. Vol. 115, N 3. P. 453 - 474.

25. H. et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel//Blood. 2017. Vol. 129, N 4. P. 424 - 447.

26. Olsen R.J. et al. Acute leukemia immunohistochemistry: a systematic diagnostic approach.//Arch. Pathol. Lab. Med. 2008. Vol. 132, N 3. P. 462 - 475.

27. Bene M.C. et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL).//Leukemia. 1995. Vol. 9, N 10. P. 1783 - 1786.

28. Wu D. et al. Efficacy and safety of different doses of cytarabine in consolidation therapy for adult acute myeloid leukemia patients: A network meta-analysis//Sci. Rep. 2017. Vol. 7, N 1. P. 9509.

29. Ravandi F., Walter R.B., Freeman S.D. Evaluating measurable residual disease in acute myeloid leukemia.//Blood Adv. 2018. Vol. 2, N 11. P. 1356 - 1366.

30. Лобанова Т.И., Гальцева И.В., Паровичникова Е.Н. Исследование минимальной остаточной болезни у пациентов с острыми миелоидными лейкозами методом многоцветной проточной цитофлуориметрии (обзор литературы)//Онкогематология. 2018. Vol. 13, N 1. P. 83 - 102.

31. Лобанова Т.И. "Клиренс опухолевого клона у пациентов с разными молекулярно-генетическими вариантами острых миелоидных лейкозов": диссертация... кандидата медицинских наук: 14.01.21. 2018. 166 p.

32. Herrmann J. et al. Evaluation and management of patients with heart disease and cancer: Cardio-oncology//Mayo Clin. Proc. 2014. Vol. 89, N 9. P. 1287 - 1306.

33. Roberts A.S. et al. Extramedullary haematopoiesis: radiological imaging features//Clinical Radiology. 2016. Vol. 71, N 9. P. 807 - 814.

34. Fritz J. et al. Radiologic spectrum of extramedullary relapse of myelogenous leukemia in adults.//AJR. Am. J. Roentgenol. 2007. Vol. 189, N 1. P. 209 - 218.

35. Arrigan M. et al. Imaging findings in recurrent extramedullary leukaemias//Cancer Imaging. 2013. Vol. 13, N 1. P. 26 - 35.

36. Almond L.M. et al. Myeloid Sarcoma: Presentation, Diagnosis, and Treatment//Clinical Lymphoma, Myeloma and Leukemia. Elsevier Inc., 2017. Vol. 17, N 5. P. 263 - 267.

37. Winestone L.E. et al. Disparities in pediatric acute myeloid leukemia (AML) clinical trial enrollment//Leuk. Lymphoma. Taylor and Francis Ltd, 2019. Vol. 60, N 9. P. 2190 - 2198.

38. Perel Y. et al. Treatment of childhood acute myeloblastic leukemia: Dose intensification improves outcome and maintenance therapy is of no benefit - Multicenter studies of the French LAME ( Aigu Enfant) Cooperative Group//Leukemia. Nature Publishing Group, 2005. Vol. 19, N 12. P. 2082 - 2089.

39. Rasche M. et al. Successes and challenges in the treatment of pediatric acute myeloid leukemia: a retrospective analysis of the AML-BFM trials from 1987 to 2012//Leukemia. Nature Publishing Group, 2018. Vol. 32, N 10. P. 2167 - 2177.

40. Шнейдер М.М. Эффективность риск-адаптированной терапии острого миелоидного лейкоза у детей с использованием режимов интенсивного тайминга и трансплантации гемопоэтических стволовых клеток. Диссертация на соискание ученой степени доктора медицинских наук. 2009. 223 p.

41. R. et al. Practical aspects of the use of intrathecal chemotherapy Aspectos pr cticos de la utilizaci n de quimioterapia intratecal//Farm Hosp. 2017. Vol. 41, N 1. P. 105 - 129.

42. Creutzig U. et al. CNS irradiation in pediatric acute myleoid leukemia: Equal results by 12 or 18 Gy in studies AML-BFM98 and 2004//Pediatr. Blood Cancer. 2011. Vol. 57, N 6. P. 986 - 992.

43. Stevens R.F. et al. Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukaemia: Results of the United Kingdom Medical Research Council's 10th AML trial//Br. J. Haematol. 1998. Vol. 101, N 1. P. 130 - 140.

44. Ravindranath Y. et al. Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): A review of four consecutive childhood AML trials conducted between 1981 and 2000//Leukemia. Nature Publishing Group, 2005. Vol. 19, N 12. P. 2101 - 2116.

45. Kardos G. et al. Treatment strategy and results in children treated on three Dutch Childhood Oncology Group acute myeloid leukemia trials//Leukemia. Nature Publishing Group, 2005. Vol. 19, N 12. P. 2063 - 2071.

46. Smith F.O. et al. Long-term results of children with acute myeloid leukemia: A report of three consecutive Phase III trials by the Children's Cancer Group: CCG 251, CCG 213 and CCG 2891//Leukemia. Nature Publishing Group, 2005. Vol. 19, N 12. P. 2054 - 2062.

47. Perel Y. et al. Maintenance therapy in childhood acute myeloid leukemia//Ann. Hematol. 2004. Vol. Supp. 1. P. S116 - S119.

48. Toyama D. et al. Successful Treatment of Pediatric Refractory/Relapsed AML with KIR-Ligand-Mismatched Cord Blood Transplant after FLAG-IDA Reinduction Therapy with or without the GO Regimen//Case Rep. Hematol. Hindawi Limited, 2020. Vol. 2020.

49. Hashmi K.U. et al. FLAG-IDA in the treatment of refractory/relapsed acute leukaemias: Single centre study//J. Pak. Med. Assoc. 2005. Vol. 55, N 6. P. 234 - 238.

50. Safaian N.N. et al. Sorafenib () induces molecular remission and regression of extramedullary disease in a patient with FLT3-ITD+ acute myeloid leukemia//Leuk. Res. 2009. Vol. 33, N 2. P. 348 - 350.

51. Osone S. et al. Sorafenib Therapy for Pediatric Acute Myeloid Leukemia with FMS-like Tyrosine Kinase 3-internal Tandem Duplication Mutations: 2 Case Reports//J. Pediatr. Hematol. Oncol. Lippincott Williams and Wilkins, 2017. Vol. 39, N 4. P. e199 - e202.

52. Crews K.R. et al. Interim comparison of a continuous infusion versus a short daily infusion of cytarabine given in combination with cladribine for pediatric acute myeloid leukemia//J. Clin. Oncol. 2002. Vol. 20, N 20. P. 4217 - 4224.

53. Румянцев А.Г., Масчан А.А., Самочатова Е.В. Сопроводительная терапия и контроль инфекций при гематологических и онкологических заболеваниях. 2009. 448 p.

54. Coiffier B. et al. Guidelines for the management of pediatric and adult tumor lysis syndrome: An evidence-based review//Journal of Clinical Oncology. 2008. Vol. 26, N 16. P. 2767 - 2778.

55. Cairo M.S. et al. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: An expert TLS panel consensus//Br. J. Haematol. 2010. Vol. 149, N 4. P. 578 - 586.

56. Детская онкология. Национальное руководство. Под ред. М.Д. Алиева, В.Г. Полякова, Г.Л. Менткевича, С.А. Маяковой. М.: Издательская группа РОНЦ. Практическая медицина, 2012. 684 p.

57. Maertens J. et al. ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients//J. Antimicrobal Chemother. 2016. Vol. 71, N 9. P. 2397 - 2404.

58. Chen M. et al. Pyridoxine for Prevention of Hand-Foot Syndrome Caused by Chemotherapy: A Systematic Review//PLoS One. Public Library of Science, 2013. Vol. 8, N 8.

59. Korula A. et al. Invasive fungal infection following chemotherapy for acute myeloid leukaemia-Experience from a developing country//Mycoses. Blackwell Publishing Ltd, 2017. Vol. 60, N 10. P. 686 - 691.

60. Fisher B.T. et al. Effect of Caspofungin vs Fluconazole Prophylaxis on Invasive Fungal Disease among Children and Young Adults with Acute Myeloid Leukemia: A Randomized Clinical Trial//JAMA - J. Am. Med. Assoc. American Medical Association, 2019. Vol. 322, N 17. P. 1673 - 1681.

61. Mandhaniya S. et al. Oral voriconazole versus intravenous low dose amphotericin B for primary antifungal prophylaxis in pediatric acute leukemia induction: A prospective, randomized, clinical study//J. Pediatr. Hematol. Oncol. 2011. Vol. 33, N 8. P. e333 - 41.

62. Cornely O.A. et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia//N. Engl. J. Med. Massachussetts Medical Society, 2007. Vol. 356, N 4. P. 348 - 359.

63. Ueda M. et al. Immunoglobulin therapy in hematologic neoplasms and after hematopoietic cell transplantation.//Blood Rev. 2018. Vol. 32, N 2. P. 106 - 115.

64. Nellis M.E., Goel R., Karam O. Transfusion Management in Pediatric Oncology Patients//Hematology/Oncology Clinics of North America. W.B. Saunders, 2019. Vol. 33, N 5. P. 903 - 913.

65. Szczepiorkowski Z.M., Dunbar N.M. Transfusion guidelines: when to transfuse.//Hematology/the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. 2013. Vol. 2013. P. 638 - 644.

66. Абузарова Г.Р. et al. Обезболивание взрослых и детей при оказании медицинской помощи. Методические рекомендации. ФГБОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России., 2016. 94 p.

67. Paul K.L. Rehabilitation and exercise considerations in hematologic malignancies.//Am. J. Phys. Med. Rehabil. 2011. Vol. 90, N 5 Suppl 1. P. S88 - 94.

68. Tramsen L. et al. Lack of effectiveness of neutropenic diet and social restrictions as anti-infective measures in children with acute myeloid leukemia: An analysis of the AML-BFM 2004 trial//J. Clin. Oncol. American Society of Clinical Oncology, 2016. Vol. 34, N 23. P. 2776 - 2783.

69. Milligan D.W. et al. Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: Results of the MRC AML-HR randomized trial//Blood. American Society of Hematology, 2006. Vol. 107, N 12. P. 4614 - 4622.

70. Gibson B.E.S. et al. Results of a randomized trial in children with Acute Myeloid Leukaemia: Medical Research Council AML12 trial//Br. J. Haematol. 2011. Vol. 155, N 3. P. 366 - 376.

71. Creutzig U. et al. Toxicity and effectivity of high-dose Idarubicin during AML induction therapy: Results of a pilot study in children//Klin. Padiatr. 2000. Vol. 212, N 4. P. 163 - 168.

72. Creutzig U. et al. Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: Results of study acute myeloid Leukemia-Berlin-Frankfurt- 93//J. Clin. Oncol. Lippincott Williams and Wilkins, 2001. Vol. 19, N 10. P. 2705 - 2713.

73. Acute myeloid leukemia. NCCN evidence blocks. 2020.

74. Uffmann M. et al. Therapy reduction in patients with Down syndrome and myeloid leukemia: the international ML-DS 2006 trial//Blood. American Society of Hematology, 2017. Vol. 129, N 25. P. 3314 - 3321.

75. Cornelissen J.J. et al. The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: An integrated-risk adapted approach//Nature Reviews Clinical Oncology. 2012. Vol. 9, N 10. P. 579 - 590.